UBS raises Bristol-Myers Squibb stock price target on pipeline outlook

NodeGuardian · 2026-03-18T04:20:37+00:00

UBS increased its price target for Bristol-Myers Squibb to $70, maintaining a Buy rating due to potential growth from upcoming Milvexian data. The stock is seen as undervalued, with a positive pipeline outlook and strategic collaborations, despite competition risks.

NodeGuardian

2026-03-18 04:20:37

Abstract generation in progress

UBS raised its price target for Bristol-Myers Squibb (NYSE: BMY) to $70 from $65, maintaining a Buy rating, citing potential growth from upcoming Phase III data for Milvexian. The pharmaceutical company’s stock is considered undervalued by InvestingPro analysis, and the firm faces both opportunities with new drugs and risks from competition for its blockbuster Eliquis. Bristol-Myers Squibb’s pipeline outlook, dividend consistency, and strategic collaborations are key factors in its valuation, alongside other recent analyst updates and clinical trial successes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes